



Balfour Capital Group BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a global biotech firm headquartered in San Rafael, CA, specializing in enzyme replacement therapies and other treatments for rare genetic diseases. Founded in 1997, it has developed multiple orphan drugs and operates worldwide with robust R&D pipelines.

1. Top 5 Competitors

BioMarin competes principally in rare-disease therapeutics with peers including:

- Orchard Therapeutics
- Regenxbio
- Lexeo
- Exelixis
- Roche, Amgen, Biogen, Gilead, Alexion

2. Largest Institutional Shareholders

Major institutional stakeholders include:

- BlackRock (~12.4% ownership)
- Vanguard (~9.9%)
- PRIMECAP Management (~9.3%)
- Dodge & Cox (~7.8%)
- Viking Global Investors (~5.6%)
- Additionally, State Street, Capital Research, among others hold substantial positions .

3. Management Team

Executive leadership includes:

- Alexander Hardy, CEO & President
- Brian R. Mueller, EVP & CFO
- Greg Friberg, M.D., EVP & Chief R&D Officer
- C. Greg Guyer, EVP & Chief Technical Officer
- Cristin Hubbard, EVP & Chief Commercial Officer
- G. Eric Davis, EVP & General Counsel
- Marni Kottle, EVP, Corporate Affairs
- Amy Wireman, EVP, People Operations
- James Sabry, EVP & Chief Business Officer



Balfour Capital Group BioMarin Pharmaceutical Inc.

4. Revenue

- FY 2023 revenue: \$2.419 billion
- FY 2024 revenue: \$2.854 billion (18% YoY growth)
- Trailing twelve months through Q1 2025: \$2.95 billion .
- Q4 2024 alone: \$747 million (+16% YoY)
- Q1 2025: \$745 million (+15% YoY) .

5. Institutions with Buy Recommendations:

Analyst consensus is predominantly positive:

- “Moderate Buy” consensus from 23 of 29 analysts
- MarketBeat: 17 Buy, 6 Hold, 0 Sell ratings
- MarketWatch: Average recommendation “Overweight,” target ~\$96.8 Benzinga:
- Median price target ~\$95, “Strong Buy” sentiment Specific institutions aren't listed by name, but most top-tier brokers maintain buy/overweight ratings.

6. Analyst Sentiment Summary

Overall sentiment: Bullish, with average sentiment ranging from Moderate Buy to Strong Buy.

- Average price target is around \$95–\$96, implying 70% upside from current (\$55) .
- Target range: \$65 to \$122

7. Insider Buying and Selling (Last 24 Months)

- Significant insider selling: 246,669 shares sold, totaling ~\$21 million. Sellers included CFO Brian Mueller, CTO Greg Guyer, CLO G. Eric Davis, ex-R&D head Henry Fuchs, Chairman Jean-Jacques Bienaime, among others .
- Notable insiders sold: George Eric Davis (\$7.7M), Bienaime (\$7.2M), Fuchs (~\$4.1M) .
- Insider buying: Limited data. No significant purchases reported in 24 months; recent SEC filings show minimal insider buying activity